US006376544B2

(12) **United States Patent**
Lowry et al.

(10) **Patent No.: US 6,376,544 B2**
(45) **Date of Patent: Apr. 23, 2002**

(54) **NUTRITIONAL PRODUCT FOR A PERSON HAVING RENAL FAILURE**

(75) Inventors: **Carol Jo Lowry**, Minneapolis; **Kathy Marie Sass**, Forest Lake, both of MN (US)

(73) Assignee: **Novartis Nutrition AG**, Berne (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/775,727**

(22) Filed: **Feb. 2, 2001**

Related U.S. Application Data

(63) Continuation of application No. 09/078,165, filed on May 13, 1998, now Pat. No. 6,288,116.

(51) **Int. Cl.**[7] **A61K 31/195**

(52) **U.S. Cl.** **514/565**; 562/516; 562/562; 426/648

(58) **Field of Search** 514/565; 426/648; 562/516, 562

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,957,938	A		9/1990	Anderson et al.	514/412
5,108,767	A		4/1992	Mulchandani et al.	426/72
5,221,668	A		6/1993	Henningfield et al.	514/23
5,438,042	A		8/1995	Schmidl et al.	514/21
5,550,146	A	*	8/1996	Acosta et al.	514/400
5,576,287	A	*	11/1996	Zaloga et al.	514/2
5,714,472	A	*	2/1998	Gray et al.	514/21
5,719,133	A	*	2/1998	Schmidl et al.	514/58
5,719,134	A	*	2/1998	Schmidl et al.	514/58
5,728,678	A	*	3/1998	Trimbo et al.	514/12
5,731,290	A	*	3/1998	Schneider	514/20
5,776,913	A	*	7/1998	Ogilvie et al.	514/57
5,780,039	A	*	7/1998	Greenberg et al.	424/400
5,780,439	A	*	7/1998	Mendy et al.	514/21
5,874,106	A	*	2/1999	Adedotun et al.	424/456
5,922,766	A	*	7/1999	Acosta et al.	514/561
6,288,116	B1	*	9/2001	Lowry et al.	514/565

FOREIGN PATENT DOCUMENTS

EP	0 747 395		12/1996
WO	95/29675		11/1995
WO	9733568	*	9/1997
WO	9804256	*	2/1998
WO	9832428	*	7/1998

OTHER PUBLICATIONS

Berkow et al. (eds.), *The Merck Manual of Diagnosis and Therapy*, 16th Edition, Merck & Co., Rahway, NJ, 1992, only pp. 1661–1668 and 1684–1702 supplied.*

Reyes et al., "Role of Arginine in Health and in Renal Disease," *American Journal of Physiology (Renal,Fluid and Electrolyte Physiology*, vol. 36(3)), 267(No. 3, Pt. 2), F331–F346 (Sep. 1994).*

Derwent Abstracts, 97–299788/28, DE 29703380–UI , Jun. 5, 1997.

Derwent Abstracts, 80–11994C/07,JP 5–5002–625, Jan. 10, 1980.

Derwent Abstracts, 79–69979B/39, BE 876263, Sep. 3, 1979.

Derwent Abstracts, 97–409877/38, JP 09182573–A, Jul. 15, 1997.

Derwent Abstracts, 91–231122/32, DE 4002–204–A , Aug., 1991.

Derwent Abstracts, 89–079981/11, JP 0 1030–558–A, Feb. 1, 1989.

Derwent Abstracts, 89–020278/03, JP 6 3296–663–A, Dec. 2, 1988.

Food Service Resource, Resource Renal Beverage, Novartis Nutrition, 1998, Literature.

O. Mareckova, et al., Czech Med, vol. 4 Nos. 1–2, pp. 81–90 (1981) published PubMed Abstract.

L. Schramm, et al., Ren Fail, vol. 16, No. 5, pp. 555–69 (1994) published PubMed.

PW Sanders, Blood Purif, vol. 13, Nos. 3–4, pp. 219–227 (1995) published PubMed.

* cited by examiner

Primary Examiner—James O. Wilson
Assistant Examiner—Lawrence E Crane
(74) *Attorney, Agent, or Firm*—Michael U. Lee; John D. Thallemer

(57) **ABSTRACT**

L-arginine found essential to enhance the glomerular function of the kidneys is used ϕ formulate a low viscosity, calorie-dense, nutritional product for a person having renal failure. In a product free of citric acid or citrates, for oral ingestion, the taste of arginine is counteracted by lactic, malic or adipic acid; in a formulation for tube-feeding, citric acid and citrates in a specified ratio controls the product's stability. The ratio of calcium to phosphorus is controlled, as is the caloric distribution and water content; the amounts of vitamins and minerals included provide a nutritionally complete formulation.

7 Claims, 2 Drawing Sheets